Summary
BHC Chart
Why Is Bausch (BHC) Down 13% Since Last Earnings Report?
Bausch (BHC) reported earnings 30 days ago. What's next for the stock?
Bausch Health Announces 2025 Annual Meeting of Shareholder Results
LAVAL, QC / ACCESS Newswire / May 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the election of the 10 directors nominated at its 2025 annual meeting of shareholders ("Annual Meeting") held on May 13, 2025. The detailed results of the vote for the election of directors are set out below: Name For Withheld Broker Non-Votes Thomas J.
Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down
BHCs first-quarter 2025 adjusted earnings and revenues miss estimates. Salix performs lower than expected.
Bausch Health Companies Inc. Dividends
 BHC 10 Nov 2010 Paid | Other | CA$1 Per Share |
| BHC 30 Aug 2010 Paid | Quarterly | CA$0.1 Per Share |
| BHC 31 May 2010 Paid | Quarterly | CA$0.1 Per Share |
| BHC 4 Mar 2010 Paid | Quarterly | CA$0.09 Per Share |
| BHC 30 Nov 2009 Paid | Quarterly | CA$0.09 Per Share |
Bausch Health Companies Inc. Earnings
| 30 Jul 2025 (53 Days) Date | | - Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 20 Feb 2025 Date | | 1.13 Cons. EPS | 1.16 EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| 30 Oct 2024 Date | | 1.06 Cons. EPS | 1.13 EPS |
| BHC 10 Nov 2010 Paid | Other | CA$1 Per Share |
| BHC 30 Aug 2010 Paid | Quarterly | CA$0.1 Per Share |
| BHC 31 May 2010 Paid | Quarterly | CA$0.1 Per Share |
| BHC 4 Mar 2010 Paid | Quarterly | CA$0.09 Per Share |
| BHC 30 Nov 2009 Paid | Quarterly | CA$0.09 Per Share |
| 30 Jul 2025 (53 Days) Date | | - Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 20 Feb 2025 Date | | 1.13 Cons. EPS | 1.16 EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| 30 Oct 2024 Date | | 1.06 Cons. EPS | 1.13 EPS |
Bausch Health Companies Inc. (BHC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Bausch Health Companies Inc. ever had a stock split?
Bausch Health Companies Inc. Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Thomas J. Appio CEO | TSX Exchange | CA0717341071 ISIN |
| CA Country | 20,700 Employees | 11 Jun 2014 Last Dividend | 16 Oct 2000 Last Split | - IPO Date |
Overview
Bausch Health Companies Inc. is a global player in the specialized pharmaceutical and medical device sector, with operations spanning both the United States and numerous other countries around the world. Its focus areas include gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. Originally known as Valeant Pharmaceuticals International, Inc., the company underwent a name change in July 2018, marking a new chapter in its history. Headquartered in Laval, Canada, the organization functions through five key segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb, each targeting specific market needs.
Products and Services
Bausch Health's diverse portfolio extends across various medical domains, including:
- Gastroenterology: Under the Salix segment, the company provides innovative products aimed at gastrointestinal health, catering primarily to the US market.
- International Pharmaceutical and Medical Devices: The International segment encompasses the distribution of branded and generic pharmaceuticals, OTC products, and aesthetic medical devices across different countries, focusing on meeting global health needs.
- Aesthetic Medical Devices: Through the Solta Medical segment, Bausch Health engages in the development and sale of cutting-edge aesthetic devices, showcasing its commitment to advancing beauty and dermatological care.
- Diversified Products: The Diversified segment offers a wide range of pharmaceuticals in neurology and various other therapeutic classes, including generic products, ortho dermatologic products, and dentistry products within the US. This diversification underscores the company's holistic approach to healthcare.
- Vision Care and Ophthalmic Products: The Bausch + Lomb segment, named after the well-known eye health brand, provides a comprehensive line of products to address vision care, surgical requirements, and ophthalmic pharmaceutical needs, underlining Bausch Health's prominence in eye health solutions.
Contact Information
